From Phase 1 + Phase 2a published data

• Local (most common, mild and transient): application-site redness, mild itch, occasional irritation. No serious skin reactions reported.
• Systemic: none — by design, no detectable blood levels at therapeutic dose
• Serious adverse events: none reported in Phase 2a (n=78, 12-week follow-up)
• Allergic dermatitis: theoretically possible with any topical; not reported as systematic

Theoretical and unstudied concerns

• Long-term repeated stem-cell activation. PP-405's mechanism repeatedly pushes HFSCs into activation. Whether chronic activation produces:
  • Stem-cell exhaustion (running out of HFSC pool over decades)
  • Dysregulated proliferation (any neoplasia signal)
  • Catagen acceleration on the back end ...is completely unknown. No trial has run beyond 3 months yet. This is the highest-priority unknown.
• Off-target metabolic effects. MPC inhibition affects systemic metabolism in models (intestinal stem cells, hepatocytes, etc.). PP-405's blood instability is the safety mechanism — but if formulation degrades, manufacturing differs, or compromised skin barriers (severe AGA scalp inflammation, microneedling, abraded skin) increase systemic uptake, this protection is lost.
• Microneedling + PP-405 stacking. Plausible combination for users wanting to enhance penetration, but microneedling could compromise the blood-instability safety profile. Speculative concern, no data.
• Hair color / pigment effects. Some metabolic-pathway interventions affect melanocyte function. No reports yet.
• Female-pattern AGA in pregnancy. Topical only with no systemic exposure SHOULD make this safer than finasteride or minoxidil in pregnancy, but trials excluded pregnancy and no data exist. Hard-blocked in fit-criteria pending clarity.

Specific watch periods (when sourcing is real)

• First 7 days for any allergic dermatitis
• Week 4 reassessment for early Ki67 signal (if accessible) and any unexpected systemic symptom
• Week 8-12 for efficacy readout
• Long-term (year+): unknown — no data exist